Kestrel's $1.45 billion AbbVie Deal, FDA Approves First Ever PROTAC, and Werewolf Breaks Arsenal Lease.
Plus more details on Windgap's big pharma partnership and a number of people moves.
Parallel Bio's Expansion into Therapeutics, and We're Looking Out for More Potential Cash Flow Challenges -Watertown Bio News RoundUp
Plus, where key opinion leaders see Watertown's biotech sector heading.
Watertown's Emerging Rare Blood Disorder Therapy Cluster, Warning Signs For Werewolf, and Fallout for Disc Medicines-Watertown Bio News RoundUp
Join us next week in Charting Watertown’s Life Science Future
Labshares Expanding to Watertown
Neumora's Wegovy alternative, Dyno announces manufacturing pact, and more
Welcome to Watertown Bio
Soufflé Therapeutics Launches from Stealth, Disc and Werewolf receive FDA priority, Affini-T may be winding down.